LU93312I2 - Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate - Google Patents

Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate Download PDF

Info

Publication number
LU93312I2
LU93312I2 LU93312C LU93312C LU93312I2 LU 93312 I2 LU93312 I2 LU 93312I2 LU 93312 C LU93312 C LU 93312C LU 93312 C LU93312 C LU 93312C LU 93312 I2 LU93312 I2 LU 93312I2
Authority
LU
Luxembourg
Prior art keywords
salt
migalastat
chlorhydrate
including salt
Prior art date
Application number
LU93312C
Other languages
English (en)
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93312(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of LU93312I2 publication Critical patent/LU93312I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Ecology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU93312C 2006-05-16 2016-11-16 Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate LU93312I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80108906P 2006-05-16 2006-05-16
US85363106P 2006-10-23 2006-10-23
PCT/US2007/069046 WO2007137072A2 (fr) 2006-05-16 2007-05-16 Dosages biologiques pour le diagnostic et l'évaluation d'options de traitement de la maladie de fabry

Publications (1)

Publication Number Publication Date
LU93312I2 true LU93312I2 (fr) 2017-01-26

Family

ID=38723987

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93312C LU93312I2 (fr) 2006-05-16 2016-11-16 Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate

Country Status (19)

Country Link
US (9) US7851143B2 (fr)
EP (6) EP2533050B3 (fr)
JP (7) JP2009537149A (fr)
AU (1) AU2007253900A1 (fr)
CA (1) CA2652553C (fr)
CY (3) CY1115180T1 (fr)
DK (3) DK3457135T3 (fr)
ES (4) ES2573498T3 (fr)
FI (1) FI3457135T3 (fr)
HK (1) HK1218955A1 (fr)
HU (3) HUE027569T2 (fr)
LT (2) LT3457135T (fr)
LU (1) LU93312I2 (fr)
MX (2) MX351004B (fr)
NL (1) NL300843I2 (fr)
PL (3) PL3457135T3 (fr)
PT (2) PT2533050E (fr)
SI (3) SI2533050T1 (fr)
WO (1) WO2007137072A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009537149A (ja) 2006-05-16 2009-10-29 アミークス セラピューティックス インコーポレイテッド ファブリー病に対する治療の選択を診断し、評価するためのアッセイ
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2008134628A2 (fr) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Schémas posologiques pour le traitement de maladies de stockage lysosomal en utilisant des chaperons pharmacologiques
WO2009102895A2 (fr) * 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Méthode de prédiction de la réponse de certaines maladies a un traitement pharmacologique à base de chaperon moléculaire
WO2009114712A2 (fr) * 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Analyses permettant de diagnostiquer et d’évaluer des options de traitement pour la maladie de pompe
AR079057A1 (es) * 2009-11-17 2011-12-21 Baylor Res Inst Triaosilceramida urinaria (gb3) como marcador de enfermedad cardiaca
AU2011223706A1 (en) * 2010-03-05 2012-09-20 Baylor Research Institute Involvement of androgen/androgen receptor pathway in Fabry disease
US20140219986A1 (en) * 2011-03-11 2014-08-07 Amicus Therapeutics ,Inc. Dosing regimens for the treatment of fabry disease
RS58718B1 (sr) 2011-05-12 2019-06-28 Proteostasis Therapeutics Inc Regulatori proteostaze
ES2864774T3 (es) * 2011-12-22 2021-10-14 Centogene Ip Gmbh Combinación de un compuesto que tiene la capacidad de reorganizar una enzima lisosomal y Ambroxol y/o un derivado de Ambroxol
WO2013112706A1 (fr) 2012-01-25 2013-08-01 Proteostasis Therapeutics, Inc. Composés permettant de moduler l'activité de protéasome
WO2014127038A1 (fr) * 2013-02-12 2014-08-21 Baylor Research Institute Procédés et compositions associés à l'homéostase du calcium et la maladie de fabry
WO2015097088A1 (fr) * 2013-12-23 2015-07-02 Bcn Peptides, S.A. Analogues du bicalutamide ou (s)-bicalutamide en tant que composés activant l'exocytose pour leur utilisation dans le traitement d'un trouble de surcharge lysosomale ou de la glycogenèse
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
CA2955297C (fr) 2014-07-25 2025-07-08 Takeda Pharmaceutical Company Limited Structure cristalline du domaine similaire à une protéine de transfert de glycolipide de protéine 2 adaptatrice à quatre phosphates humaine
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
AU2017298376A1 (en) * 2016-07-19 2019-03-07 Amicus Therapeutics, Inc. Treatment of Fabry disease in ERT-naive and ERT-experienced patients
US12020820B1 (en) 2017-03-03 2024-06-25 Cerner Innovation, Inc. Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en) 2017-03-06 2022-05-17 Cerner Innovation, Inc. Predicting glycogen storage diseases (Pompe disease) and decision support
PT4324522T (pt) * 2017-05-30 2026-03-13 Amicus Therapeutics Inc Métodos de tratamento de pacientes com fabry tendo insuficiência renal
KR20220116305A (ko) 2017-05-30 2022-08-22 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
US11923048B1 (en) 2017-10-03 2024-03-05 Cerner Innovation, Inc. Determining mucopolysaccharidoses and decision support tool
EP3749307B1 (fr) 2018-02-06 2025-12-10 Amicus Therapeutics, Inc. Utilisation de migalastat pour le traitement de la maladie de fabry chez des patientes enceintes
PT3749308T (pt) * 2018-02-06 2024-01-25 Amicus Therapeutics Inc Tratamento de pacientes com doença de fabry clássica com migalastato
EP3814336A1 (fr) 2018-06-27 2021-05-05 Proteostasis Therapeutics, Inc. Composés améliorant l'activité du protéasome
AU2019295765B2 (en) 2018-06-27 2024-08-29 Yumanity, Inc. Proteasome activity enhancing compounds
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP4289476A3 (fr) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Méthodes de traitement de la maladie de fabry chez les patients porteurs d'une mutation du gène gla
WO2021026447A1 (fr) 2019-08-07 2021-02-11 Amicus Therapeutics, Inc. Méthodes de traitement de la maladie de fabry chez les patients porteurs d'une mutation du gène gla
US11191827B1 (en) 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463109A4 (en) * 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
CA2086413A1 (fr) 1990-06-29 1991-12-30 Yohji Ezure Derives piperidine
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US5900360A (en) 1996-04-10 1999-05-04 Welch; William J. Correction of genetic defects using chemical chaperones
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
PT2857036T (pt) 2003-01-31 2017-03-13 Mount Sinai School Of Medicine Of N Y Univ Terapia combinada para o tratamento de distúrbios de deficiência proteica
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
WO2004103368A1 (fr) 2003-05-22 2004-12-02 The Hospital For Sick Children Traitement des maladies de tay sachs ou de sandhoff par renforcement de l'activite d'une hexosaminidase
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
BRPI0416216A (pt) 2003-11-12 2006-12-26 Amicus Therapeutics Inc composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
AU2006247065B8 (en) 2005-05-17 2012-07-12 Amicus Therapeutics, Inc. A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
US7973157B2 (en) 2005-06-08 2011-07-05 Amicus Therapeutics, Inc. Imino and amino sugar purification
MX2007015602A (es) 2005-06-08 2008-02-21 Amicus Therapeutics Inc Tratamiento de trastornos del sistema nervioso central asociados con mutaciones en genes que codifican las enzimas lisosomicas.
CA2616537A1 (fr) 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Petits composes corrigeant un mauvais repliement des proteines et utilisations de ceux-ci
WO2007089591A2 (fr) 2006-01-27 2007-08-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions et méthodes pour criblage à haut débit de chaperons pharmacologiques
JP2009537149A (ja) 2006-05-16 2009-10-29 アミークス セラピューティックス インコーポレイテッド ファブリー病に対する治療の選択を診断し、評価するためのアッセイ
UA94624C2 (uk) 2006-09-22 2011-05-25 Крка, Товарна Здравіл, Д.Д., Ново Мєсто Арипіпразолу геміфумарат і спосіб його одержання
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
WO2008134628A2 (fr) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Schémas posologiques pour le traitement de maladies de stockage lysosomal en utilisant des chaperons pharmacologiques
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (fr) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Méthode de prédiction de la réponse de certaines maladies a un traitement pharmacologique à base de chaperon moléculaire
WO2010048532A1 (fr) 2008-10-24 2010-04-29 Amicus Therapeutics, Inc. Modèle de dosage à multiples compartiments
WO2010138608A1 (fr) 2009-05-26 2010-12-02 Amicus Therapeutics, Inc. Utilisation de chaperons pharmacologiques pour améliorer la fabrication et la purification de produits biologiques
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
AR079057A1 (es) 2009-11-17 2011-12-21 Baylor Res Inst Triaosilceramida urinaria (gb3) como marcador de enfermedad cardiaca
US20140219986A1 (en) 2011-03-11 2014-08-07 Amicus Therapeutics ,Inc. Dosing regimens for the treatment of fabry disease
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
HK1209625A1 (en) 2012-07-17 2016-04-08 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
KR20190087673A (ko) 2016-03-22 2019-07-24 아미쿠스 세라퓨틱스, 인코포레이티드 Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
AU2017298376A1 (en) 2016-07-19 2019-03-07 Amicus Therapeutics, Inc. Treatment of Fabry disease in ERT-naive and ERT-experienced patients
TW201829770A (zh) 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
KR20220116305A (ko) 2017-05-30 2022-08-22 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
WO2019017938A1 (fr) 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. Traitement de la maladie de fabry chez des patients non soumis à une thérapie enzymatique substitutive (tes) et chez des patients soumis à tes
PT3675853T (pt) 2017-08-28 2022-11-28 Amicus Therapeutics Inc Métodos para melhorar e/ou estabilizar a função cardíaca em pacientes com doença de fabry
EP3749307B1 (fr) 2018-02-06 2025-12-10 Amicus Therapeutics, Inc. Utilisation de migalastat pour le traitement de la maladie de fabry chez des patientes enceintes
PT3749308T (pt) 2018-02-06 2024-01-25 Amicus Therapeutics Inc Tratamento de pacientes com doença de fabry clássica com migalastato
EP4289476A3 (fr) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Méthodes de traitement de la maladie de fabry chez les patients porteurs d'une mutation du gène gla
BR112021024886A2 (pt) 2019-06-11 2022-01-25 Amicus Therapeutics Inc Métodos de tratar a doença de fabry em pacientes com insuficiência renal
WO2021026447A1 (fr) 2019-08-07 2021-02-11 Amicus Therapeutics, Inc. Méthodes de traitement de la maladie de fabry chez les patients porteurs d'une mutation du gène gla

Also Published As

Publication number Publication date
DK2533050T3 (da) 2014-06-02
WO2007137072A2 (fr) 2007-11-29
EP2955520A1 (fr) 2015-12-16
PL2533050T3 (pl) 2014-08-29
EP2024745B1 (fr) 2015-07-08
JP2025060691A (ja) 2025-04-10
HK1218955A1 (en) 2017-03-17
HUS1600048I1 (hu) 2017-01-30
EP4541418A2 (fr) 2025-04-23
WO2007137072A3 (fr) 2008-10-16
SI2533050T1 (sl) 2014-07-31
EP2024745A2 (fr) 2009-02-18
EP2787345B1 (fr) 2016-02-24
US20150238474A1 (en) 2015-08-27
EP2533050B3 (fr) 2015-06-24
LTPA2016033I1 (lt) 2016-12-12
DK3457135T3 (da) 2025-02-24
JP2020196717A (ja) 2020-12-10
US20080056994A1 (en) 2008-03-06
US9987263B2 (en) 2018-06-05
CY1117656T1 (el) 2017-05-17
JP2023027053A (ja) 2023-03-01
MX2008014679A (es) 2009-04-14
AU2007253900A1 (en) 2007-11-29
JP2009537149A (ja) 2009-10-29
JP2016006088A (ja) 2016-01-14
US11241422B2 (en) 2022-02-08
EP4541418A3 (fr) 2025-07-09
US20220160690A1 (en) 2022-05-26
DK2787345T3 (en) 2016-05-30
ES2709445T3 (es) 2019-04-16
US20190388409A1 (en) 2019-12-26
NL300843I2 (fr) 2016-12-21
EP2955520B1 (fr) 2018-10-31
JP6800176B2 (ja) 2020-12-16
ES2464527T7 (es) 2015-09-14
MX351004B (es) 2017-09-26
LT3457135T (lt) 2025-05-12
US10383864B2 (en) 2019-08-20
CA2652553A1 (fr) 2007-11-29
HK1178975A1 (en) 2013-09-19
PL3457135T3 (pl) 2025-06-09
PT3457135T (pt) 2025-02-04
CA2652553C (fr) 2020-08-18
US9480682B2 (en) 2016-11-01
PL2533050T6 (pl) 2016-05-31
US10406143B2 (en) 2019-09-10
HK1129458A1 (en) 2009-11-27
PL2787345T3 (pl) 2016-08-31
ES2573498T3 (es) 2016-06-08
JP6026268B2 (ja) 2016-11-16
HUE027569T2 (en) 2016-10-28
US7851143B2 (en) 2010-12-14
JP2013100307A (ja) 2013-05-23
CY2016040I1 (el) 2017-06-28
US20120220632A1 (en) 2012-08-30
CY2016040I2 (el) 2017-06-28
EP3457135A1 (fr) 2019-03-20
EP2787345A1 (fr) 2014-10-08
JP7175297B2 (ja) 2022-11-18
DK2533050T6 (da) 2015-09-21
ES3012794T3 (en) 2025-04-10
LTC2787345I2 (lt) 2017-10-10
EP2024745A4 (fr) 2010-03-17
EP3457135B1 (fr) 2024-12-04
PT2533050E (pt) 2014-05-26
CY1115180T1 (el) 2016-12-14
US9000011B2 (en) 2015-04-07
HUE071237T2 (hu) 2025-08-28
US20110104727A1 (en) 2011-05-05
ES2464527T9 (es) 2015-07-24
FI3457135T3 (fi) 2025-03-08
SI3457135T1 (sl) 2025-07-31
US20170042868A1 (en) 2017-02-16
EP2533050B1 (fr) 2014-03-12
JP2018138564A (ja) 2018-09-06
SI2787345T1 (sl) 2016-08-31
US20180325881A1 (en) 2018-11-15
US20180250279A1 (en) 2018-09-06
EP2533050A1 (fr) 2012-12-12
ES2464527T3 (es) 2014-06-03
EP2787345B8 (fr) 2016-04-13

Similar Documents

Publication Publication Date Title
LU92568I2 (fr) Siméprévir, ou un sel de celui-ci, y compris le sodium siméprévir
LU93327I2 (fr) Opicapone ou un sel pharmaceutiquement acceptable de celui-ci
LU92672I2 (fr) Fluralaner ou un de ses sels
EP2298747A4 (fr) Dérivé de triazole ou sel de celui-ci
LU92864I2 (fr) Cobicistat ou un de ses sels pharmaceutiquement acceptables
LU92785I2 (fr) Céritinib ou un sel pharamceutiquement acceptable de celui-ci
BRPI0815588A2 (pt) Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
BRPI0810086A2 (pt) inibidores de tirosina quinase de bruton
EP2124523A4 (fr) Lignee de laitue p2428-5006090
EP2042480A4 (fr) Dérivé d'aminoindane ou sel de celui-ci
EP1987521A4 (fr) Evaluation de confiance
EP2149561A4 (fr) Dérivé de tétrahydroisoquinolin-1-one ou sel de celui-ci
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
EP2110789A4 (fr) Processeur de papier-monnaie
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
DE602006009921D1 (de) Pigmentierter keramischer Körper
DE602008000396D1 (de) Wandaufhänger
EP1906944A4 (fr) Preparation de schisandrine b
NO20055643D0 (no) Preparation of lodixanol
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas
DE502007003774D1 (de) Werkzeugaufnahme
EP2013346A4 (fr) Espèces de pestivirus
ITMI20061048A1 (it) Procedimento per la preparazione di magnesio boroidruro cristallino
FR2877833B1 (fr) Correcteur de lordoses